Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleCHEMOTHERAPY, ANTIBIOTICS, AND GENE THERAPY

Optimizing the Dosing Schedule of TNP-470 [O-(Chloroacetyl-carbamoyl) Fumagillol] Enhances Its Antitumor and Antiangiogenic Efficacies

Satoru Koyanagi, Hiroo Nakagawa, Yukako Kuramoto, Shigehiro Ohdo, Shinji Soeda and Hiroshi Shimeno
Journal of Pharmacology and Experimental Therapeutics February 2003, 304 (2) 669-674; DOI: https://doi.org/10.1124/jpet.102.043562
Satoru Koyanagi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hiroo Nakagawa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yukako Kuramoto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shigehiro Ohdo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shinji Soeda
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hiroshi Shimeno
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Many drugs vary in potency and/or toxicity according to the time of day when they are administered. In this study, we investigated whether antitumor efficacy of angiogenesis inhibitor, TNP-470 [O-(chloroacetyl-carbamoyl) fumagillol], could be improved by optimizing the dosing schedule. Tumor-bearing mice were housed under standardized light/dark cycle conditions (lights on at 7:00 AM, off at 7:00 PM) with food and water ad libitum. The antitumor effect of TNP-470 (30 mg/kg s.c.) was more potent in mice injected with the drug at the early light phase than it was when administered at the early dark phase. The diurnal change in the antitumor effect of TNP-470 was parallel to that in its antiangiogenic activity. The variation in the effects of TNP-470 was closely related to the diurnal variations in its inhibitory action on methionine aminopeptidase activity in tumor masses. There was a significant dosing time-dependent change in the concentration of TNP-470 in plasma. The higher concentration of TNP-470 in plasma was observed when its antitumor and antiangiogenic activities were increased. These results suggest that therapeutic efficacy of TNP-470 can be enhanced by choosing the most appropriate time of day to administer the drug.

Footnotes

  • This study was supported by a grant-in-aid for Encouragement of Young Scientists from the Japan Society for the Promotion of Science (S.K., 13771448), a grant-in-aid from Japan Research Foundation for Clinical Pharmacology (S.K.), and a grant-in aid from Takeda Science Foundation (S.K.).

  • DOI: 10.1124/jpet.102.043562

  • Abbreviations:
    TNP-470
    O-(chloroacetyl-carbamoyl) fumagillol
    MetAP-2
    methionine aminopeptidase
    Met-MCA
    methionine 4-methyl coumary-7-amide
    AMC
    7-amino-4-methylcoumarin
    NONMEM
    nonlinear mixed effect model
    AUC
    area under the plasma concentration-time curve
    AGM-1883
    fumagillol carbamate
    • Received September 3, 2002.
    • Accepted October 25, 2002.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 304 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 304, Issue 2
1 Feb 2003
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Optimizing the Dosing Schedule of TNP-470 [O-(Chloroacetyl-carbamoyl) Fumagillol] Enhances Its Antitumor and Antiangiogenic Efficacies
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleCHEMOTHERAPY, ANTIBIOTICS, AND GENE THERAPY

Optimizing the Dosing Schedule of TNP-470 [O-(Chloroacetyl-carbamoyl) Fumagillol] Enhances Its Antitumor and Antiangiogenic Efficacies

Satoru Koyanagi, Hiroo Nakagawa, Yukako Kuramoto, Shigehiro Ohdo, Shinji Soeda and Hiroshi Shimeno
Journal of Pharmacology and Experimental Therapeutics February 1, 2003, 304 (2) 669-674; DOI: https://doi.org/10.1124/jpet.102.043562

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleCHEMOTHERAPY, ANTIBIOTICS, AND GENE THERAPY

Optimizing the Dosing Schedule of TNP-470 [O-(Chloroacetyl-carbamoyl) Fumagillol] Enhances Its Antitumor and Antiangiogenic Efficacies

Satoru Koyanagi, Hiroo Nakagawa, Yukako Kuramoto, Shigehiro Ohdo, Shinji Soeda and Hiroshi Shimeno
Journal of Pharmacology and Experimental Therapeutics February 1, 2003, 304 (2) 669-674; DOI: https://doi.org/10.1124/jpet.102.043562
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Sodium pentobarbital suppresses breast cancer
  • Off-Target Effect of PDE Inhibitors on Colon Cancer
  • Ixazomib Suppresses Esophageal Squamous Cell Carcinoma
Show more Chemotherapy, Antibiotics, and Gene Therapy

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics